Lumateperone - Latest Advances

Efficacy of Lumateperone in Depression Associated With Bipolar II Disorder: A Pooled Analysis of Late-Phase Clinical Trials.

Journal: CNS spectrums

Published: September 29, 2025

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.

Journal: The Journal of clinical psychiatry

Published: August 28, 2025

Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials.

Journal: Journal of psychopharmacology (Oxford, England)

Published: August 28, 2025

Electroconvulsive Therapy for Treatment-Resistant Late-Onset Bipolar Disorder.

Journal: Cureus

Published: August 13, 2025

Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial.

Journal: International clinical psychopharmacology

Published: July 22, 2025

Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study.

Journal: International clinical psychopharmacology

Published: July 15, 2025

Is Lumateperone Effective in Bipolar Depression? A Systematic Literature Review and Meta-Analysis on Placebo-Controlled Trials.

Journal: Pharmacopsychiatry

Published: July 14, 2025

Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review.

Journal: CNS drugs

Published: June 26, 2025

Reply to Letter From Surekha et al: "Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions".

Journal: Journal of clinical psychopharmacology

Published: May 29, 2025

Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions.

Journal: Journal of clinical psychopharmacology

Published: May 29, 2025

Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis.

Journal: CNS drugs

Published: May 12, 2025

Efficacy and safety of adjunctive therapy with lumateperone in major depressive disorder: a randomized-, double-blind, placebo-controlled clinical trial.

Journal: International clinical psychopharmacology

Published: April 17, 2025

Filters

Efficacy of Lumateperone in Depression Associated With Bipolar II Disorder: A Pooled Analysis of Late-Phase Clinical Trials.

Efficacy of Lumateperone in Depression Associated With Bipolar II Disorder: A Pooled Analysis of Late-Phase Clinical Trials.

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.

Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials.

Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials.

Electroconvulsive Therapy for Treatment-Resistant Late-Onset Bipolar Disorder.

Electroconvulsive Therapy for Treatment-Resistant Late-Onset Bipolar Disorder.

Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial.

Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial.

Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study.

Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study.

Is Lumateperone Effective in Bipolar Depression? A Systematic Literature Review and Meta-Analysis on Placebo-Controlled Trials.

Is Lumateperone Effective in Bipolar Depression? A Systematic Literature Review and Meta-Analysis on Placebo-Controlled Trials.

Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review.

Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review.

Reply to Letter From Surekha et al: "Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions".

Reply to Letter From Surekha et al: "Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions".

Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions.

Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions.

Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis.

Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis.

Efficacy and safety of adjunctive therapy with lumateperone in major depressive disorder: a randomized-, double-blind, placebo-controlled clinical trial.

Efficacy and safety of adjunctive therapy with lumateperone in major depressive disorder: a randomized-, double-blind, placebo-controlled clinical trial.